Response to tovorafenib in patients with PD while on a MAPKi as their most recent prior therapy (post hoc analysis)
crieria
A post hoc analysis was completed using all three radiological criteria to assess responses to tovorafenib in patients who received a MAPKi as their most recent line of therapy and discontinued due to progression. For RANO-HGG criteria, 33% (n = 15) of patients who had progressed on a MAPKi as their most recent prior therapy had a CR or a PR to tovorafenib; similar trends were observed for RAPNO and RANO-LGG crieria, which include MRs: 33% (